Physician profile
Michael B Gold
NPI 1174566244
$1,587.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $216 · 2021: $339 · 2022: $136 · 2023: $450 · 2024: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $362.67 | 2019-2022 | |
| Horizon Therapeutics Plc | $247.03 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $156.02 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $150.28 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $90.17 | 2021 | |
| Bausch & Lomb Americas INC. | $84.14 | 2022-2024 | Vyzulta, Miebo |
| Aerie Pharmaceuticals, INC. | $82.54 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $79.85 | 2020-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.44 | 2019-2021 | |
| Allergan, INC. | $54.92 | 2020-2021 | |
| Alcon Vision LLC | $46.20 | 2022-2024 | Simbrinza |
| Amgen INC. | $44.90 | 2024 | Tepezza |
| Shire North American Group INC | $21.93 | 2019 | |
| Harrow Eye, LLC | $20.95 | 2024 | Vevye |
| Biotissue Holdings INC. | $20.85 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $19.63 | 2019 | |
| Thea Pharma INC. | $17.89 | 2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $14.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.